Article
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial.
Med (New York, N.Y.) - 10 Jan 2025
Zhou Qing, Yu Yan, Xing Ligang, Cheng Ying, Wang Ying, Pan Yueyin, Fan Yun, Shi Jianhua, Zhang Guojun, Cui Jiuwei, Zhou Jianying, Song Yong, Zhuang Wu, Ma Zhiyong, Hu Yanping, Li Gaofeng, Dong Xiaorong, Feng Jifeng, Lu Shun, Wu Jingxun, Li Juan, Zhang Longzhen, Wang Dong, Xu Xinhua, Yang Tsung-Ying, Yang Nong, Guo Yubiao, Zhao Jun, Yao Yu, Zhong Diansheng, Xia Bing, Yang Cheng-Ta, Zhu Bo, Sun Ping, Shim Byoung Yong, Chen Yuan, Wang Zhen, Ahn Myung-Ju, Wang Jie, Wu Yi-Long
Abstract excerpt
BACKGROUND: Zorifertinib (AZD3759), an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) with high blood-brain barrier penetration capability, demonstrated promising intracranial and systemic antitumor activity in phase 1 and 2 studies in central nervous system (CNS)-metastatic patients. METHODS: In this phase 3 EVEREST trial (ClinicalTrials.gov: NCT03653546), patients with EGFR-sensitizing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.